Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 7, Pages 3604-3657Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00208
Keywords
-
Categories
Ask authors/readers for more resources
New drugs introduced to the market are privileged structures with affinities for biological targets implicated in human diseases, providing insights into molecular recognition and guiding future drug design.
New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available